Neutropenia with Ibrance, Kisqalu and Verzenio.
Cyclin-dependent kinase (CDK) 4/6 inhibitors are a class of anticancer medications that can reduce or eliminate endocrine resistance when used in combination with endocrine therapy for the treatment of hormone receptorpositive (HR+) breast cancer. Currently, three CDK4/6 inhibitors are approved for the initial treatment of HR+ advanced breast cancer in combination with an aromatase inhibitor (AI): abemaciclib,[1] palbociclib,[2] or ribociclib[3. Ibrance (palbociclib alo has an incidence of around 80% in the PALOMA trials.Rates of neutropenia in patients receiving abemaciclib were 41% (22%, grade > 3) in MONARCH-3, 46% (32%, grade > 3) in MONARCH-2, and 37% (27%, grade > 3) in MONARCH-1. As such, there is a contrindication to trying Ibrance after aa pateitn developed nutropenia on ribiciclib, becaseu teh change of again developing neutropenia is very high.
Pramanik R, Sahoo RK, Gogia A. Neutropenia due to palbociclib: A word of caution?. Indian J Med Paediatr Oncol. 2016;37(3):206. doi:10.4103/0971-5851.190351
https://www.cancernetwork.com/breast-cancer/management-neutropenic-toxicity-cdk46-inhibitors, 1/2019